Kanglong Chemical plans to repurchase 200 million to 300 million yuan of A shares
Kanglong Chemical (03759) announced that in order to maintain the company's value and the rights of the company's shareholders, enhance investor confidence, and comprehensively consider factors such as the company's financial situation, future development and reasonable valuation level, the company plans to use its own funds to repurchase A-shares. The repurchase price of shares shall not exceed RMB 31/share (inclusive), and the total repurchase capital shall not be less than RMB 200 million (inclusive) and not more than RMB 300 million (inclusive). The repurchase of A-shares is intended to be used to cancel and reduce the company's registered capital. According to the estimated total capital for repurchasing shares of RMB 200 million to RMB 300 million, the repurchase price of shares does not exceed RMB 300 million
China Resources Pharmaceutical (03320.HK): Donga Ejiao's net profit of 353 million yuan in the first quarter increased 53.43% year-on-year
Gelonghui, April 26 | China Resources Pharmaceutical (03320.HK) announced that Donga Ejiao (000423.SZ)'s revenue for the first quarter of 2024 was 1,453 billion yuan, up 35.95% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) was 353 million yuan, up 53.43% year on year; net profit attributable to shareholders of listed companies (Donga Ejiao) after deducting non-recurring profit and loss was 329 million yuan, up 54.79% year on year; basic earnings per share were 0.5488 yuan.
華潤醫藥:公告東阿阿膠截至2024年3月31日止三個月的未經審核財務業績
華潤醫藥:公告華潤雙鶴截至2024年3月31日止三個月的未經審核財務業績
石藥集團:2023年度報告
Sino Biopharm Completes Phase I Study of Hepatitis B Drug
Sino Biopharmaceutical (HKG:1177) said it recently successfully completed the phase I clinical study of its self-developed drug TQA3038 (siRNA), according to a Thursday filing with the Hong Kong Excha